Navigation Links
Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
Date:12/3/2010

EAST HANOVER, N.J., Dec. 3, 2010 /PRNewswire/ -- A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa® (zoledronic acid) significantly improved overall survival (OS) and progression-free survival (PFS) in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs) (1,2).

The published results are from Medical Research Council (MRC) Myeloma IX, a large, randomized, Phase III clinical trial of nearly 2,000 patients with multiple myeloma (1). These results were initially reported at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, in June 2010.

At a median follow-up of 3.7 years, Zometa significantly reduced the risk for death by 16% (hazard ratio [HR] 0.842; 95% confidence interval [CI] 0.74-0.96; P=0.0118) and the relative risk for PFS events by 12% (HR 0.88; 0.80-0.98; P=0.0179) compared with oral clodronate. In addition to demonstrating superiority to clodronate on survival endpoints, Zometa was significantly superior to clodronate in the prevention of SREs associated with multiple myeloma, regardless of SRE history at baseline (1).

More than 750,000 cases of multiple myeloma are diagnosed each year worldwide, with a median overall survival of three to five years (3). Nearly 95% of advanced stage multiple myeloma patients have bone disease and half of them will experience SREs (e.g., pathologic fractures, radiation or surgery to bone, spinal cord compression) if not treated (4,5).

"As a hematologist who treats patients with multiple myeloma, the survival benefit demonstrated by Zometa in this study is very encouraging," said Professor Gareth Morgan, Head of Haemato-oncology at The Royal Marsden and The Institute of Cancer Research, UK and one of the study's lead in
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
2. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
3. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
4. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
5. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
6. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
7. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
8. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
9. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
10. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
11. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and ... Interconnects and Packaging (EMIP) Division. "I am ... general management and business development experience, especially in the ... important contributions to the continued growth and success of ...
(Date:7/25/2014)... , July 25, 2014 Leading ... is returning for the seventh year to São Paulo, ... 7 th August 2014. The event will co-locate with ... most comprehensive meeting point for the pharmaceutical industry. ... top 25 countries for pharmaceutical sales are now exploring the ...
(Date:7/25/2014)... July 25, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... corporate update and report second quarter 2014 financial results ... August 1, 2014. That same day, Arena will host ... Time (5:30 a.m. Pacific Time). The ... domestic callers and 914.495.8552 for international callers. Please specify ...
Breaking Medicine Technology:AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
... Nov. 4 HeartWare International, Inc. (Nasdaq: HTWR ... less invasive, miniaturized circulatory support technologies revolutionizing the treatment ... in revenues to $7.5 million for the third quarter ... million in revenues in the second quarter ended June ...
... , THOUSAND OAKS, Calif., Nov. 4 Amgen (Nasdaq: ... applications for its 19th annual Amgen Award for Science ... recognize and honor extraordinary science teachers at the K-12 ... teaching and who achieve demonstrated results in student learning ...
Cached Medicine Technology:HeartWare International Reports Third Quarter Revenues of $7.5 Million 2HeartWare International Reports Third Quarter Revenues of $7.5 Million 3HeartWare International Reports Third Quarter Revenues of $7.5 Million 4HeartWare International Reports Third Quarter Revenues of $7.5 Million 5HeartWare International Reports Third Quarter Revenues of $7.5 Million 6HeartWare International Reports Third Quarter Revenues of $7.5 Million 7Call for Applications: The Amgen Award for Science Teaching Excellence 2Call for Applications: The Amgen Award for Science Teaching Excellence 3
(Date:7/25/2014)... NC (PRWEB) July 25, 2014 Researchers at ... the results of a study indicating that a man-made material ... mesothelioma among workers exposed to asbestos. Surviving Mesothelioma has just ... to read it now. , The French scientists ... developed mesothelioma between 1987 and 2006. One group of ...
(Date:7/25/2014)... 25, 2014 Healthpointe is proud ... clinic is offering Occupational Medicine services to the ... accepting referrals and workers’ compensation cases. , ... clinic include wound care treatment management, return-to-work and ... pre-employment screening & physicals, and illness and injury ...
(Date:7/25/2014)... the leading pan-European association representing medical oncology professionals, ... Data Protection Regulation [1] could make cancer research ... doctors and cancer patients. , The proposed wording ... patient consent, meaning that researchers would have to ... in order to consult their data or use ...
(Date:7/25/2014)... Yisrayl Hawkins, Pastor and Overseer of The House of Yahweh ... revealing to the whole world, including even the most devout ... in his new article. , Yisrayl says it all started ... by the Catholic Church. He says this plan included removing ... and replacing it with titles such as Lord and God. ...
(Date:7/25/2014)... According to the Addict Him To You Pdf ... guide that teaches women how to get the love of ... its review that this book consists of 4 parts, including:, ... won’t commit yet (and what to do about it) , ... ,     Part 3: How to touch his heart ...
Breaking Medicine News(10 mins):Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 2Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 3Health News:Healthpointe Offering Occupational Medicine Services in La Mirada 2Health News:Is Europe putting cancer research at risk? 2Health News:Yisrayl Hawkins Says You Have Been Tricked Into Worshipping Satan in New Article 2Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 2Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 3
... -- A program that helps elementary school students develop ... science and cultural studies may be one way to ... United States. In a new study, researchers assessed ... in which students explore, prepare and enjoy fresh, affordable ...
... 2011 A two-year study of patients in the ... (TAVR) in patients who have severe aortic stenosis and ... one-year findings and support the role of TAVR as ... today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) ...
... NOVEMBER 10, 2011 Results of the PARTNER ... replacement (TAVR) results in improved quality of life compared ... the transfemoral approach. The results of the study were ... (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. ...
... thinking about Parkinson,s disease is that it,s a disorder of ... brain,s substantia nigra to die or become impaired. A study ... a hereditary form of Parkinson,s disease cause mitochondria to run ... to stop them. Findings appear in the November 11 issue ...
... physicians for increasing the volume of visits and procedures ... health outcomes," the American College of Physicians (ACP) today ... Pensions (HELP) in a hearing on Improving Quality, Lowering ... does not provide incentives for physicians to coordinate care; ...
... News) -- All the color variations seen in prehistoric ... populations, which indicates that the ancient human artists accurately ... The research is also the first to provide ... Previous DNA studies produced evidence only for bay (reddish ...
Cached Medicine News:Health News:Cooking Class Benefits Kids in Many Ways 2Health News:Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011 2Health News:Quality of life benefits of transcatheter aortic valve replacement differ by access site 2Health News:Why do neurons die in Parkinson's disease? 2Health News:Internists express strong support for ACA's programs to support coordinated care 2Health News:Cave Art Accurately Depicted Horses of Different Colors 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: